Protective characteristics of COVID-19 convalescent and post-vaccination IgG antibodies
Klegerman, M. E.; Peng, T.; Seferovich, I.; Rahbar, M. H.; Hessabi, M.; Tahanan, A.; Wanger, A.; Grimes, C. Z.; Ostrosky-Zeichner, L. Z.; Koster, K.; Cirillo, J. D.; Abeydeera, D.; De Lira, S.; McPherson, D. D.
Show abstract
Soon after commencement of the SARS-CoV-2 disease outbreak of 2019 (COVID-19), it became evident that the receptor-binding domain of the viral spike protein is the target of neutralizing antibodies that comprise a critical element of protective immunity to the virus. This study addresses the relative lack of information regarding actual antibody concentrations in convalescent plasma samples from COVID-19 patients and extends these analyses to post-vaccination samples to estimate protective IgG antibody (Ab) levels. Both sample populations were similar and a protective Ab level of 7.5 {micro}g/ml was determined, based on 95% of the normal distribution of the post-vaccination population. The results of this study have implications for future vaccine development, projection of protective efficacy duration, and understanding of the immune response to SARS-CoV-2 infection. One-Sentence SummaryUsing two quantitative immunoassays, we have found similar IgG antibody responses to the SARS-CoV-2 spike protein in populations of COVID-19 survivors and vaccine recipients that indicate a protective antibody concentration.
Matching journals
The top 6 journals account for 50% of the predicted probability mass.
Similar papers in this journal
- Clinical utility of Elecsys Anti-SARS-CoV-2 S assay in COVID-19 vaccination: An exploratory analysis of the mRNA-1273 phase 1 trial 97%
- Detection of Antibody Responses against SARS-CoV-2 in Plasma and Saliva from Vaccinated and Infected Individuals 96%
- Kinetics and persistence of the cellular and humoral immune responses to BNT162b2 mRNA vaccine in SARS-CoV-2-naive and - experienced subjects 95%
Similar papers in this journal
- Rapid and Quantitative Detection of Human Antibodies Against the 2019 Novel Coronavirus SARS CoV2 and its Variants as a Result of Vaccination and Infection 96%
- SARS-CoV-2 Convalescent Sera Binding and Neutralizing Antibody Concentrations Compared with COVID-19 Vaccine Efficacy Estimates Against Symptomatic Infection 95%
- High resolution linear epitope mapping of the receptor binding domain of SARS-CoV-2 spike protein in COVID-19 mRNA vaccine recipients 95%
Similar papers in this journal
- Impact of serum versus anticoagulant-containing plasma on influenza virusneuraminidase-based serological assays 95%
- Modulation of immunosuppressant drug treatment to improve SARS-CoV-2 vaccine efficacy in mice 95%
- Safety and Immunogenicity of An Egg-Based Inactivated Newcastle Disease Virus Vaccine Expressing SARS-CoV-2 Spike: Interim Results of a Randomized, Placebo-Controlled, Phase 1/2 Trial in Vietnam 95%
Similar papers in this journal
- Bamlanivimab does not neutralize two SARS-CoV-2 variants carrying E484K in vitro 94%
- Elite neutralizers of human cytomegalovirus are characterized by high magnitude plasma IgG responses against multiple glycoprotein complexes 94%
- SARS-CoV-2 seroassay optimization and performance in a population with high background reactivity in Mali 94%
Similar papers in this journal
- Immunogenic Amino Acid Motifs and Linear Epitopes of COVID-19 mRNA Vaccines 96%
- A novel assessment method for COVID-19 humoral immunity duration using serial measurements in naturally infected and vaccinated subjects 95%
- Does a humoral correlate of protection exist for SARS-CoV-2? A systematic review 95%
"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.